Course info
Sections
General
0 activities
Oral and Poster Abstracts
0 activities
113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Mechanistic Insights into Sickle Cell Pathobiology and Disease Progression
7 activities
321. Coagulation and Fibrinolysis: Basic and Translational: Deciphering new and old conundrums of coagulation
7 activities
332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Risk Assessment and Management of Thromboembolism in Cancer: Genomics, Biomarkers, and Real-World Evidence
6 activities
508. Bone Marrow Failure Acquired: Immune dysregulation and molecular insights
7 activities
614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Prognostic Genetic and Therapeutic Response Factors in Adult and Pediatric B-ALL
6 activities
617. Acute Myeloid Leukemias: Commercially Available Therapies: Frontline treatment with intensive or lower-intensity regimens
7 activities
621. Lymphomas: Translational – Molecular and Genetic - Subtyping strategies to unlock new therapeutic vulnerabilities
6 activities
627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies - Front-line BTKi-based Combination Therapy in DLBCL and PCNSL
7 activities
629. Aggressive Lymphomas, Immunotherapy including Bispecific Antibodies: Overcoming Barriers in Frontline Therapy: Bispecific Antibodies for Older Adults with DLBCL
7 activities
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Precision targeting in MPN
6 activities
632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Decoding the Molecular Drivers of response and resistance
6 activities
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Expanding the Therapeutic and Prognostic Landscape in Myeloproliferative Neoplasms, Mastocytosis and Hypereosinophilic Syndrome
6 activities
653. Multiple Myeloma: Clinical and Epidemiological: Optimizing Immune-Based Therapies in Myeloma: From T-Cell Fitness to Clinical Outcomes
7 activities
654. Multiple Myeloma: Pharmacologic Therapies: Advancing the Standard: Improving Myeloma Treatment through Diagnosis, Maintenance and Relapse
7 activities
702. CAR-T Cell Therapies: Basic and Translational: In vivo CAR-T cell platforms and resistance mechanisms
6 activities
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Improving Outcomes by Decreasing Transplant-Related Complications
7 activities
803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Transformative AI and Omics Approaches in Hematologic Malignancies
7 activities
900. Health Services and Quality Improvement: Hemoglobinopathies: Transforming Care Delivery and the Patient Experience
7 activities
906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Clinical decision making and supportive care
6 activities
907. Outcomes Research: Plasma Cell Disorders: Real-world Outcomes of Targeted Immunotherapies in Patients with Multiple Myeloma
6 activities
615. Acute Myeloid Leukemias: Clinical and Epidemiological: Biological and Clinical Nuances in Patient Outcomes
7 activities
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Treatment of CLL in Relapse and in Richter Transformation
7 activities
603. Lymphoid Oncogenesis: Basic - Mechanistic studies of lymphoid leukemias and lymphomas
7 activities
622. Lymphomas: Translational - Non-Genetic: Insights into immune niches of CNS and Hodgkin Lymphoma via multi-omic and spatial profiling
6 activities
624. Hodgkin Lymphomas: Clinical and Epidemiological: Improving Outcomes in Hodgkin Lymphoma Utilizing Targeted Therapeutics, Prognostic Modeling, and Predictive Tools
7 activities
701. Experimental Transplantation: Basic and Translational: GVHD, thymopoiesis and the host regenerative response
7 activities
723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Donor selection and maintenance strategies
7 activities
904. Outcomes Research: Hemoglobinopathies: Clinical Phenotypes and Outcomes in Hemoglobinopathies
7 activities
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Optimizing Outcomes in Pediatric, Adolescent and Young Adult Patients
6 activities
101. Red Cells and Erythropoiesis, Excluding Iron: Nursing erythropoiesis in sickness and in health
7 activities
201. Granulocytes, Monocytes, and Macrophages: Histiocytic and granulocytic Disorders
5 activities
301. Platelets and Megakaryocytes: Basic and Translational: Novel mechanisms of platelet signaling
7 activities
330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Thrombosis and thrombotic microangiopathy: New mechanisms and new therapies
6 activities
501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Chromatin and transcriptional regulation in hematopoietic lineage commitment
7 activities
602. Myeloid Oncogenesis: Basic: Identification of new vulnerabilities in therapy-resistant AML
6 activities
618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Redefining AML: Genetic, Phenotypic and Response-Based Insights
7 activities
623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: FL and WM
7 activities
636. Myelodysplastic Syndromes: Basic and Translational: Innovative Approaches to Target Novel Vulnerabilities in MDS Pathobiology
6 activities
637. Myelodysplastic Syndromes: Clinical and Epidemiological: Treatment Advances in Higher Risk Myelodysplastic Syndromes
7 activities
641. Chronic Lymphocytic Leukemia: Basic and Translational: Clonal evolution, tumor microenvironment and immunotherapy
7 activities
655. Multiple Myeloma: Cellular Therapies: Clinical Trial Advances in CAR T-Cell Therapy for Multiple Myeloma
6 activities
703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Cellular Immunotherapy Beyond CAR-T: Emerging Platforms and Strategies
7 activities
704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Next Generation CAR-T Clinical Trials in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma and Multiple Myeloma
7 activities
722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Acute and Chronic GVHD and Immune Reconstitution
7 activities
902. Health Services and Quality Improvement: Lymphoid Malignancies: Barriers and bridges: Improving access to hematologic cancer care across diverse populations
7 activities
654. Multiple Myeloma: Pharmacologic Therapies: Advances in Treatment Strategies for Relapsed/Refractory Multiple Myeloma
6 activities
803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: MRD Assays and Novel Drug Discovery Pipelines
6 activities
908. Outcomes Research: Myeloid Malignancies: Real-World Outcomes in AML
7 activities
114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Prognosis, the heart, and the kidney in SCD
7 activities
322. Hemophilia A and B: Clinical and Epidemiological: Prophylaxis Across the Age Spectrum
6 activities
323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Novel Insights into Diagnostics and Therapeutics of Bleeding in Inherited, Acquired Coagulopathies and BDUC
7 activities
332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Thrombosis and Bleeding: Real-World Insights Across Diverse Patient Populations
6 activities
605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Beyond Genomic Resistance: epigenetics, metabolism and more
7 activities
614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Critical biomarkers and classifiers in B-ALL and T-ALL ontogeny and outcomes
7 activities
619. Acute Myeloid Leukemias: Disease Burden and Measurable Residual Disease in Prognosis and Treatment: From Detection to Decision: MRD as the Compass in AML
7 activities
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Drivers, vulnerabilities and resistance in CML and MPN
6 activities
653. Multiple Myeloma: Clinical and Epidemiological: Genomic and Cytogenetic Drivers of Prognosis in Multiple Myeloma
7 activities
801. Gene Therapies: Advances in Gene Therapy for Blood Disorders
7 activities
802. Chemical Biology and Experimental Therapeutics: Novel therapeutics in hematologic malignancies?
7 activities
907. Outcomes Research: Plasma Cell Disorders: Innovations in Myeloma: Therapy, Prevention & Patient-Centered Care
7 activities
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Novel strategies to overcome therapy resistance in AML
6 activities
618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Novel AML Biomarkers: Mechanisms, Mutations, and Targets
6 activities
621. Lymphomas: Translational – Molecular and Genetic: Towards Precision Medicine in Lymphoma: Multi-Omics Discovery of Prognostic and Predictive Biomarkers
7 activities
654. Multiple Myeloma: Pharmacologic Therapies: Are we achieving cures for multiple myeloma patients using early intervention strategies?
7 activities
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Optimizing Outcomes in Adult and Elderly Patients
7 activities
803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Prediction Models and Novel Molecular Markers
6 activities
906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: CAR-T and Bispecifics in Lymphoma - Real World Outcomes and Endpoints
7 activities
114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Orphans of an orphan disease: HbSC and HbSBeta+ sickle cell Disease
7 activities
301. Platelets and Megakaryocytes: Basic and Translational: Platelets in thromboinflammatory disorders
7 activities
330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Platelets, leukocytes, and endothelium in thrombotic and vascular disease
7 activities
506. Bone Marrow Microenvironment: The microenvironment in homeostasis and aging
7 activities
602. Myeloid Oncogenesis: Basic: Targeting the NPM1/KMT2A/Menin axis
7 activities
605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Therapy resistance across B-cell maturation - from B-ALL to myeloma
6 activities
613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Emerging Treatment Paradigms in ALL
7 activities
615. Acute Myeloid Leukemias: Clinical and Epidemiological: Lessons from across the age spectrum
5 activities
621. Lymphomas: Translational – Molecular and Genetic - Decoding Lymphomagenesis through Multiomics
7 activities
627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies - Targeted Agents and Chemotherapy Intensification in Aggressive B-cell Lymphomas
6 activities
653. Multiple Myeloma: Clinical and Epidemiological: From Biomarkers to Biology: Evolving Risk Stratification and Disease Modeling in Multiple Myeloma
7 activities
702. CAR-T Cell Therapies: Basic and Translational: Product biology and single-cell states shaping CAR-T cell outcomes
7 activities
721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Factors Influencing Transplant Outcomes
6 activities
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Biologic Predictors and Novel Platforms Integrating CAR T with Transplant
7 activities
902. Health Services and Quality Improvement: Lymphoid Malignancies: Redefining supportive care: Development of novel safety, patient engagement, and delivery models in hematologic oncology
7 activities
618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: AML Biomarkers in Action: Prognosis, Risk, and Real-World Insights
6 activities
623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological - Immunotherapies for Follicular Lymphoma
6 activities
626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: Clinical and Biological Predictors of Outcome
8 activities
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Between a Rock and a Ropeg - Innovative Therapies for MPNs
6 activities
637. Myelodysplastic Syndromes: Clinical and Epidemiological: Moving the Needle Through Novel Approaches in MDS and CMML
6 activities
102. Iron Homeostasis and Biology in Physiological and Pathological Conditions: Erythropoiesis, Inflammation and Hematologic Recovery: The Iron and Heme Drama Unfolds
7 activities
322. Hemophilia A and B: Clinical and Epidemiological: Innovations Shaping the Future of Hemophilia Care
6 activities
401. Blood Transfusion: Transfusion Frontlines: Research Driving Safer, Smarter Care
7 activities
612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Optimizing risk stratification, treatment, and diagnostics of ALL in the immunotherapy era
5 activities
622. Lymphomas: Translational - Non-Genetic: T cell interactions in the lymphoma microenvironment - the good and the bad
6 activities
625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Fresh insight for Cutaneous and Virus-associated TCLs
7 activities
628. Aggressive Lymphomas: Cellular Therapies: Clinical Insights and Determinants of Resistance to Cellular Therapies in Aggressive Lymphomas
7 activities
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Emerging Myeloma Disease Mechanisms and Therapeutic Strategies
7 activities
652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Redefining diagnosis, monitoring and treatment approaches
7 activities
723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Predicting and elucidating relapse
7 activities
901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Closing the Quality Gap: Women's Health and Rapid Testing
7 activities
908. Outcomes Research: Myeloid Malignancies: Treatment and Outcomes in the Real-World
7 activities
114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: On the Horizon: Biomarkers Guiding Outcomes in Hemoglobinopathies
7 activities
722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Biomarkers and Targets
6 activities
Plenary Scientific Session
7 activities
101. Red Cells and Erythropoiesis, Excluding Iron: Erythropoiesis: clinical relevance
6 activities
201. Granulocytes, Monocytes, and Macrophages: New findings in neutropenia and myelopoiesis
6 activities
203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: The immune system's first move: early lymphocyte development to disease states
6 activities
503. Clonal Hematopoiesis, Aging, and Inflammation: Novel approaches in suppressing clonal hematopoiesis
6 activities
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Resistance mechanisms and targeting approaches
7 activities
613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Risk Adapted Treatment and Immune Targeting for Frontline and Relapsed ALL in Pediatric and Adults
7 activities
616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Immunotherapy and chemotherapy combinations in AML
7 activities
618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis
7 activities
628. Aggressive Lymphomas: Cellular Therapies: Novel Cellular Therapeutic Strategies for Aggressive Lymphomas
6 activities
636. Myelodysplastic Syndromes: Basic and Translational: Mechanisms of MDS Initiation and Progression
6 activities
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Frontline Treatment Strategies for CLL
7 activities
652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: New therapies and treatment goals for AL amyloidosis
4 activities
654. Multiple Myeloma: Pharmacologic Therapies: Bi, Tri and Beyond: Innovations in Bispecific and Trispecific Antibodies for Multiple Myeloma
7 activities
905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Cancer, Clots and Coagulation
7 activities
907. Outcomes Research: Plasma Cell Disorders: Therapeutic Toxicity in Multiple Myeloma: Real-World Evidence and Clinical Approaches
6 activities
114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological: Advancing Therapies in Sickle Cell Disease: Finding Progress in Existing Drugs
7 activities
623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological - Novel Treatments for and Insights into Mantle Cell Lymphoma
6 activities
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Genomic, Gene Regulatory, Immune Evolution in MM
7 activities
906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Quality of Life and Supportive Care in Lymphoid Malignancies
6 activities
908. Outcomes Research: Myeloid Malignancies: Real-World Experiences
7 activities
112. Thalassemia and Globin Gene Regulation: Murine models and a clinical approach to reduce toxicity, modulate hemoglobin F and improve outcomes in thalassemia
7 activities
311. Disorders of Platelet Number or Function: Clinical and Epidemiological: The Evolving ITP Toolkit: Maximizing Efficacy, Minimizing Side Effects
7 activities
332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Innovations in Thrombosis and Bleeding: Diagnostics, Therapeutics, and Predictive Modeling
7 activities
509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: From Inheritance to Innovation
7 activities
604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Novel targets and drugs
6 activities
612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Predicting and improving outcomes in common and rare subgroups of pediatric ALL
7 activities
616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Menin inhibitors and FLT3 inhibitors in AML
6 activities
618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Decoding the Immunopathobiology of Acute Myeloid Leukemia
6 activities
625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Novel agents or therapeutic approaches in T-cell Lymphoma
7 activities
626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: Real-world data to assess CAR outcomes and frailty
7 activities
637. Myelodysplastic Syndromes: Clinical and Epidemiological: Treatment Advances in Lower risk Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms
7 activities
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: MRD Guided Therapy and Emergence of Resistance
7 activities
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: T Cell-Redirecting Therapies in Myeloma: Novel therapeutic strategies and biology
6 activities
702. CAR-T Cell Therapies: Basic and Translational: Mechanisms of CAR-T cell toxicity and persistence
6 activities
704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Emerging CAR-T Cell Therapies for Acute Leukemias and Autoimmune Diseases
7 activities
907. Outcomes Research: Plasma Cell Disorders: Special Populations in Plasma Cell Disorders: Efficacy and Safety of Therapies in Real-World Settings
6 activities
909. Education, Communication, and Workforce: Innovating to Bridge Gaps and Improve Access: Education, Communication, and Workforce in Hematology
7 activities
722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Clinical and Translational Insights
7 activities
113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Translational Therapeutics - Emerging Targets in Sickle Cell Disease
7 activities
311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Game Changers in Platelet disorders: A Look at Novel Therapies
6 activities
331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: Old Dogs, New Tricks; Advances in Thrombotic Microangiopathy Diagnosis and Treatment
6 activities
501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Metabolism and signaling in hematopoietic stem cell fate
7 activities
506. Bone Marrow Microenvironment: The microenvironment in regenerative and pre/malignant hematopoiesis
7 activities
623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Single Agent and Combination therapy for MCL
6 activities
625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: From bench to bedside and retrospective studies to inform treatment consideration in TCL
7 activities
626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: Real-World data on clinical predictors of outcome
7 activities
632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Therapeutic agents to enhance patient outcomes
7 activities
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Beyond JAK Inhibition - Therapeutic Innovation and Transplant Strategies in Myelofibrosis
5 activities
704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Optimizing CAR T-Cell Therapy: Focus on Adjuvant Strategies and Toxicity
7 activities
722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: GVHD Prevention: Post-transplant cyclophosphamide and beyond
5 activities
803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Enhancing Clinical Decision-Making with Next-Generation Molecular and Cellular Technologies
7 activities
900. Health Services and Quality Improvement: Hemoglobinopathies: From Screening to Access: Pathways to Improving Care
7 activities
905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Antithrombotic Roulette: Balancing Risk, Cost, and Care
6 activities
906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Novel topics in CAR-T and T-cell engager therapies
6 activities
908. Outcomes Research: Myeloid Malignancies: Health Disparities and Patient-Centred Care
7 activities
615. Acute Myeloid Leukemias: Clinical and Epidemiological: Optimizing Standards of Care
7 activities
617. Acute Myeloid Leukemias: Commercially Available Therapies: Pediatric, adolescent and young adult AML
7 activities
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Enhancing Immune Therapy in MM
6 activities
653. Multiple Myeloma: Clinical and Epidemiological: Novel Baseline and Dynamic Risk Factors in Multiple Myeloma
7 activities
101. Red Cells and Erythropoiesis, Excluding Iron: Erythroid differentiation
6 activities
503. Clonal Hematopoiesis, Aging, and Inflammation: New insights into inflammatory drivers of normal and clonal hematopoiesis
7 activities
508. Bone Marrow Failure Acquired: Therapeutic advancements in AA, PNH, and VEXAS
5 activities
615. Acute Myeloid Leukemias: Clinical and Epidemiological: AML Medley: Mutations, complications, classifications
7 activities
617. Acute Myeloid Leukemias: Commercially Available Therapies: Combination regimens and targeted therapies
7 activities
623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological - Follicular Lymphoma
7 activities
628. Aggressive Lymphomas: Cellular Therapies: Emerging Approaches to Enhance Cellular Therapies and Real World Outcomes in Aggressive Lymphomas
6 activities
629. Aggressive Lymphomas, Immunotherapy including Bispecific Antibodies: Improving Outcomes in Rare Large Cell Lymphomas
6 activities
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Determinants of Immunotherapy Response in Multiple Myeloma
7 activities
704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Advancing Cell Therapies in T Cell Malignancies and AML
6 activities
711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Refining CAR-T Cells and Engineered HSPCs; New Approaches to HSPC mobilization
7 activities
723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Outcomes, toxicities and late effects
7 activities
732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Precision AML Care; Reducing Relapse and Enhancing Survival
7 activities
801. Gene Therapies: Technological Developments in Gene Therapy
7 activities
901. Health Services and Quality Improvement: Non-Malignant Conditions Excluding Hemoglobinopathies: Risk Assessment, and Care Optimization, and AI, Oh my! The Spectrum of Quality in Classical Hematology
7 activities
902. Health Services and Quality Improvement: Lymphoid Malignancies: Innovations to address real-world barriers and optimize delivery of CAR-T and bispecific antibody therapies
5 activities
903. Health Services and Quality Improvement: Myeloid Malignancies: Where smarter care begins: technological innovations and quality improvement in myeloid malignancies
7 activities
904. Outcomes Research: Hemoglobinopathies: Global burden of Hemoglobinopathies: From Crisis to Care
5 activities
905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Bleeding, Barriers, and Bridging the Gaps
7 activities
602. Myeloid Oncogenesis: Basic: New insights in clonal evolution and models of disease
6 activities
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Drivers and Mast Cells and Blasts, Oh My! - Insights and Treatments for MPNs and Mastocytosis.
7 activities
653. Multiple Myeloma: Clinical and Epidemiological: Direct from podium to clinic
7 activities
183
1021